<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238885</url>
  </required_header>
  <id_info>
    <org_study_id>RCpCR-MR-Radiomics</org_study_id>
    <nct_id>NCT03238885</nct_id>
  </id_info>
  <brief_title>Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics</brief_title>
  <official_title>Predicting Pathological Complete Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy With MR Radiomics Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Ying-Shi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to construct a MR radiomics model for predicting pathological complete
      response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC)
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to develop and validate a radiomics model for individualized pCR evaluation after
      CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the
      predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The
      ultimate aim is to select appropriate LARC patients for omission of surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2013</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response(pCR)</measure>
    <time_frame>within one week after surgery</time_frame>
    <description>Pathological complete response was defined as the absence of viable tumor cells in the primary tumor and lymph nodes.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>LARC-CRT</arm_group_label>
    <description>LARC patients who will receive neoadjuvant CRT before surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pelvic MR examination</intervention_name>
    <description>All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.</description>
    <arm_group_label>LARC-CRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        LARC patients who will undergo neoadiuvant CRT before surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically proved rectal cancer

          -  locally advanced rectal cancer (â‰¥T3 or N+)

          -  a distance less than 12cm between the lower edge of tumor and the anal margin

          -  no evidence of distant metastases

          -  no prior anti-cancer therapy before treatment

          -  scheduled to receive preoperative CRT

        Exclusion Criteria:

          -  history or concurrent of other malignancy

          -  incomplete preoperative CRT

          -  failed to receive surgery or unavailable pCR assessment

          -  poor quality of MR images for measurement

          -  patient quit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying-Shi Sun</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying-Shi Sun</last_name>
    <phone>861088196822</phone>
    <email>sys27@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying-Shi Sun, MD</last_name>
      <phone>861088196822</phone>
      <email>sys27@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Sun Ying-Shi</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

